Purdue researchers create biocompatible nanoparticles to enhance systemic delivery of cancer immunotherapy

FDA approves Anktiva for non-muscle-invasive bladder cancer

FDA has approved ImmunityBio’s Anktiva (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin for the treatment of patients with BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors.

April 26, 2024

Vol.50 No.17

Drugs & Targets

Health Canada approves Keytruda for gastroesophageal cancer

Health Canada approved Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing-chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma.

April 26, 2024

Vol.50 No.17

Clinical Roundup

Clinical tool predicts immunotherapy response in uveal melanoma patients

Research from the University of Pittsburgh explains why metastatic uveal melanoma is resistant to conventional immunotherapies and how adoptive therapy, which involves growing a patient’s T cells outside the body before reinfusing them, can successfully treat this rare and aggressive cancer.

April 19, 2024

Vol.50 No.16

Funding Opportunities

SITC accepting nominations for annual awards and the Academy of Immuno-Oncology

The Society for Immunotherapy of Cancer is taking nominations for the SITC Annual Awards and the Academy of Immuno-Oncology.

April 05, 2024

Vol.50 No.14

Clinical Roundup

UTSW discovers protective ‘acid wall’ formed by cancer cells

Cancer cells release a significantly more concentrated level of acid than previously known, forming an “acid wall” that could deter immune cells from attacking tumors, UT Southwestern Medical Center scientists showed in a study.

April 05, 2024

Vol.50 No.14

Clinical Roundup

“Double life” of key immune protein reveals strategies for treating cancer and autoimmune diseases

Insights into the workings of PD-1 reveal how treatments that restrict its action can potentially be strengthened to improve their anticancer effect, a new study shows.

March 15, 2024

Vol.50 No.11

Purdue researchers create biocompatible nanoparticles to enhance systemic delivery of cancer immunotherapy

YOU MAY BE INTERESTED IN

FDA approves Anktiva for non-muscle-invasive bladder cancer

Health Canada approves Keytruda for gastroesophageal cancer

Clinical tool predicts immunotherapy response in uveal melanoma patients

SITC accepting nominations for annual awards and the Academy of Immuno-Oncology

UTSW discovers protective ‘acid wall’ formed by cancer cells

“Double life” of key immune protein reveals strategies for treating cancer and autoimmune diseases

Renew today!

Subscriber content

Login